 [
    {
        "id": 2836,
        "drug_name": "HUMIRA (adalimumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Rheumatoid Arthritis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-10-31",
        "link": "http:\/\/hugin.info\/134323\/R\/2223385\/871319.pdf",
        "note": "FDA approval announced October 31, 2018.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3870,
        "drug_name": "DSUVIA (Sufentanil)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Moderate-to-severe acute pain following a surgical procedure",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-02",
        "link": "http:\/\/ir.acelrx.com\/news-releases\/news-release-details\/acelrx-announces-fda-approval-dsuviatm",
        "note": "FDA Approval announced November 2, 2018.",
        "company_entity_id": 2346,
        "company_ticker": "TLPH",
        "company_name": "Talphera Inc.",
        "company_price": "1.0900",
        "company_change": -0.010000000000000009,
        "company_percent_change": -0.91,
        "company_optionable": 1,
        "company_number_of_shares": 16969103,
        "price_change_sparkline": [
            [
                1.04,
                1706677200
            ],
            [
                1.05,
                1706763600
            ],
            [
                0.94,
                1706850000
            ],
            [
                0.95,
                1707109200
            ],
            [
                0.8962,
                1707195600
            ],
            [
                0.87,
                1707282000
            ],
            [
                0.86,
                1707368400
            ],
            [
                0.9142,
                1707454800
            ],
            [
                1.1,
                1707714000
            ],
            [
                1.03,
                1707800400
            ],
            [
                1.03,
                1707886800
            ],
            [
                1.03,
                1707973200
            ],
            [
                1.25,
                1708059600
            ],
            [
                1.25,
                1708405200
            ],
            [
                1.22,
                1708491600
            ],
            [
                1.32,
                1708578000
            ],
            [
                1.47,
                1708664400
            ],
            [
                1.42,
                1708923600
            ],
            [
                1.37,
                1709010000
            ],
            [
                1.38,
                1709096400
            ],
            [
                1.36,
                1709182800
            ],
            [
                1.31,
                1709269200
            ],
            [
                1.3,
                1709528400
            ],
            [
                1.25,
                1709614800
            ],
            [
                1.27,
                1709701200
            ],
            [
                1.135,
                1709787600
            ],
            [
                1.125,
                1709874000
            ],
            [
                1.1,
                1710129600
            ]
        ],
        "statuses": []
    },
    {
        "id": 3870,
        "drug_name": "DSUVIA (Sufentanil)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Moderate-to-severe acute pain following a surgical procedure",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-02",
        "link": "http:\/\/ir.acelrx.com\/news-releases\/news-release-details\/acelrx-announces-fda-approval-dsuviatm",
        "note": "FDA Approval announced November 2, 2018.",
        "company_entity_id": 317,
        "company_ticker": "XOMA",
        "company_name": "XOMA Corporation",
        "company_price": "25.6500",
        "company_change": -0.63,
        "company_percent_change": -2.4,
        "company_optionable": 1,
        "company_number_of_shares": 11625826,
        "price_change_sparkline": [
            [
                19.97,
                1706677200
            ],
            [
                20.6,
                1706763600
            ],
            [
                20.2,
                1706850000
            ],
            [
                20.04,
                1707109200
            ],
            [
                20.81,
                1707195600
            ],
            [
                20.33,
                1707282000
            ],
            [
                20.04,
                1707368400
            ],
            [
                20.41,
                1707454800
            ],
            [
                20.9,
                1707714000
            ],
            [
                19.52,
                1707800400
            ],
            [
                20.4,
                1707886800
            ],
            [
                22.18,
                1707973200
            ],
            [
                23.13,
                1708059600
            ],
            [
                22.28,
                1708405200
            ],
            [
                24.5,
                1708491600
            ],
            [
                23.34,
                1708578000
            ],
            [
                23.32,
                1708664400
            ],
            [
                24.76,
                1708923600
            ],
            [
                24.36,
                1709010000
            ],
            [
                24.95,
                1709096400
            ],
            [
                24.31,
                1709182800
            ],
            [
                24.9,
                1709269200
            ],
            [
                24.97,
                1709528400
            ],
            [
                24.59,
                1709614800
            ],
            [
                25,
                1709701200
            ],
            [
                25.12,
                1709787600
            ],
            [
                24.71,
                1709874000
            ],
            [
                26.28,
                1710129600
            ],
            [
                25.65,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2564,
        "drug_name": "LORBRENA (lorlatinib)",
        "clinical_trial_id": "NCT03052608",
        "has_trial_insight_page": 0,
        "indication": "ALK+ NSCLC",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-02",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_lorbrena_lorlatinib_for_previously_treated_alk_positive_metastatic_nsclc",
        "note": "FDA approval announced November 2, 2018.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4888,
        "drug_name": "Empliciti (elotuzumab) - ELOQUENT-3",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Relapsed\/refractory multiple myeloma ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-06",
        "link": "https:\/\/news.bms.com\/press-release\/bristolmyers\/us-food-and-drug-administration-approves-empliciti-elotuzumab-plus-pomali",
        "note": "FDA approval announced November 6, 2018.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3805,
        "drug_name": "YUPELRI (revefenacin)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "COPD",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-09",
        "link": "https:\/\/investor.theravance.com\/news-releases\/news-release-details\/theravance-biopharma-and-mylan-receive-fda-approval-yupelritm",
        "note": "FDA Approval announced November 9, 2018.",
        "company_entity_id": 289,
        "company_ticker": "TBPH",
        "company_name": "Theravance Biopharma Inc.",
        "company_price": "8.5200",
        "company_change": -0.050000000000000044,
        "company_percent_change": -0.5800000000000001,
        "company_optionable": 1,
        "company_number_of_shares": 48164708,
        "price_change_sparkline": [
            [
                9.48,
                1706677200
            ],
            [
                9.16,
                1706763600
            ],
            [
                8.9,
                1706850000
            ],
            [
                8.85,
                1707109200
            ],
            [
                8.82,
                1707195600
            ],
            [
                8.5,
                1707282000
            ],
            [
                8.22,
                1707368400
            ],
            [
                8.58,
                1707454800
            ],
            [
                8.58,
                1707714000
            ],
            [
                8.35,
                1707800400
            ],
            [
                8.46,
                1707886800
            ],
            [
                8.67,
                1707973200
            ],
            [
                8.8,
                1708059600
            ],
            [
                8.92,
                1708405200
            ],
            [
                8.76,
                1708491600
            ],
            [
                8.675,
                1708578000
            ],
            [
                8.98,
                1708664400
            ],
            [
                9.23,
                1708923600
            ],
            [
                9.69,
                1709010000
            ],
            [
                9.4,
                1709096400
            ],
            [
                9.47,
                1709182800
            ],
            [
                9.44,
                1709269200
            ],
            [
                9.1,
                1709528400
            ],
            [
                8.67,
                1709614800
            ],
            [
                8.74,
                1709701200
            ],
            [
                8.69,
                1709787600
            ],
            [
                8.62,
                1709874000
            ],
            [
                8.57,
                1710129600
            ],
            [
                8.52,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4994,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Hepatocellular carcinoma (HCC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-09",
        "link": "https:\/\/bit.ly\/2qEyCeD",
        "note": "FDA approval announced November 9, 2018.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3780,
        "drug_name": "ADCETRIS (brentuximab vedotin)",
        "clinical_trial_id": "NCT01777152",
        "has_trial_insight_page": 0,
        "indication": "Frontline CD30-positive mature T-cell lymphomas - cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-16",
        "link": "http:\/\/investor.seattlegenetics.com\/news-releases\/news-release-details\/seattle-genetics-announces-fda-approval-adcetrisr-brentuximab-1",
        "note": "FDA Approval announced November 16, 2018.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3780,
        "drug_name": "ADCETRIS (brentuximab vedotin)",
        "clinical_trial_id": "NCT01777152",
        "has_trial_insight_page": 0,
        "indication": "Frontline CD30-positive mature T-cell lymphomas - cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-16",
        "link": "http:\/\/investor.seattlegenetics.com\/news-releases\/news-release-details\/seattle-genetics-announces-fda-approval-adcetrisr-brentuximab-1",
        "note": "FDA Approval announced November 16, 2018.",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4850,
        "drug_name": "PROMACTA (eltrombopag)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Severe aplastic anemia (SAA)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-16",
        "link": "http:\/\/hugin.info\/134323\/R\/2226084\/873474.pdf",
        "note": "sNDA approval announced November 16, 2018.",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4938,
        "drug_name": "DAURISMO (glasdegib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Acute myeloid leukemia (AML)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-21",
        "link": "https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/u_s_fda_approves_daurismo_glasdegib_for_adult_patients_with_newly_diagnosed_acute_myeloid_leukemia_aml_for_whom_intensive_chemotherapy_is_not_an_option",
        "note": "FDA approval announced November 21, 2018.",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5156,
        "drug_name": "VENCLEXTA (venetoclax)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First line unfit AML",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-21",
        "link": "https:\/\/www.roche.com\/media\/releases\/med-cor-2018-11-21.htm",
        "note": "FDA approval announced November 21, 2018.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5156,
        "drug_name": "VENCLEXTA (venetoclax)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First line unfit AML",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-21",
        "link": "https:\/\/www.roche.com\/media\/releases\/med-cor-2018-11-21.htm",
        "note": "FDA approval announced November 21, 2018.",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3623,
        "drug_name": "VITRAKVI (larotrectinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Solid tumors that harbor a TRK fusion.",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-26",
        "link": "https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211710s000lbl.pdf",
        "note": "FDA Approval announced November 26, 2018.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4608,
        "drug_name": "TRUXIMA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Rituxan (rituximab) biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-28",
        "link": "http:\/\/ir.tevapharm.com\/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=2378590",
        "note": "FDA Approval announced November 28, 2018.",
        "company_entity_id": 390,
        "company_ticker": "TEVA",
        "company_name": "Teva Pharmaceutical Industries Limited American Depositary Shares",
        "company_price": "13.4900",
        "company_change": 0.14,
        "company_percent_change": 1.05,
        "company_optionable": 1,
        "company_number_of_shares": 1121094011,
        "price_change_sparkline": [
            [
                12.1,
                1706677200
            ],
            [
                12.46,
                1706763600
            ],
            [
                12.28,
                1706850000
            ],
            [
                12.38,
                1707109200
            ],
            [
                12.25,
                1707195600
            ],
            [
                12.14,
                1707282000
            ],
            [
                12.09,
                1707368400
            ],
            [
                12.01,
                1707454800
            ],
            [
                12.91,
                1707714000
            ],
            [
                12.92,
                1707800400
            ],
            [
                13.17,
                1707886800
            ],
            [
                13.2,
                1707973200
            ],
            [
                13.02,
                1708059600
            ],
            [
                13.07,
                1708405200
            ],
            [
                13,
                1708491600
            ],
            [
                13.05,
                1708578000
            ],
            [
                12.89,
                1708664400
            ],
            [
                13.29,
                1708923600
            ],
            [
                13.3,
                1709010000
            ],
            [
                13.09,
                1709096400
            ],
            [
                13.15,
                1709182800
            ],
            [
                13.5,
                1709269200
            ],
            [
                13.44,
                1709528400
            ],
            [
                13.54,
                1709614800
            ],
            [
                13.53,
                1709701200
            ],
            [
                13.71,
                1709787600
            ],
            [
                13.62,
                1709874000
            ],
            [
                13.35,
                1710129600
            ],
            [
                13.49,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3230,
        "drug_name": "FIRDAPSE (amifampridine)",
        "clinical_trial_id": null,
        "has_trial_insight_page": 0,
        "indication": "Lambert-Easton Myasthenic Syndrome (LEMS)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-11-28",
        "link": "https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm627093.htm",
        "note": "FDA approval announced November 28, 2018.",
        "company_entity_id": 100,
        "company_ticker": "CPRX",
        "company_name": "Catalyst Pharmaceuticals Inc.",
        "company_price": "16.2000",
        "company_change": 0.1,
        "company_percent_change": 0.62,
        "company_optionable": 1,
        "company_number_of_shares": 117863258,
        "price_change_sparkline": [
            [
                14.4,
                1706677200
            ],
            [
                14.43,
                1706763600
            ],
            [
                13.62,
                1706850000
            ],
            [
                13.39,
                1707109200
            ],
            [
                13.75,
                1707195600
            ],
            [
                13.35,
                1707282000
            ],
            [
                13.37,
                1707368400
            ],
            [
                13.64,
                1707454800
            ],
            [
                13.64,
                1707714000
            ],
            [
                13.18,
                1707800400
            ],
            [
                13.48,
                1707886800
            ],
            [
                13.89,
                1707973200
            ],
            [
                14,
                1708059600
            ],
            [
                13.79,
                1708405200
            ],
            [
                13.71,
                1708491600
            ],
            [
                13.9,
                1708578000
            ],
            [
                14.04,
                1708664400
            ],
            [
                14.18,
                1708923600
            ],
            [
                14.35,
                1709010000
            ],
            [
                14.56,
                1709096400
            ],
            [
                16.03,
                1709182800
            ],
            [
                17.01,
                1709269200
            ],
            [
                16.69,
                1709528400
            ],
            [
                16.27,
                1709614800
            ],
            [
                15.86,
                1709701200
            ],
            [
                16.64,
                1709787600
            ],
            [
                16.25,
                1709874000
            ],
            [
                16.1,
                1710129600
            ],
            [
                16.2,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3680,
        "drug_name": "DEXTENZA",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ocular inflammation and pain following cataract surgery",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-03",
        "link": "http:\/\/investors.ocutx.com\/phoenix.zhtml?c=253650&p=irol-newsArticle&ID=2378993",
        "note": "FDA approval announced December 3, 2018.",
        "company_entity_id": 222,
        "company_ticker": "OCUL",
        "company_name": "Ocular Therapeutix Inc.",
        "company_price": "9.2900",
        "company_change": -0.43999999999999995,
        "company_percent_change": -4.52,
        "company_optionable": 1,
        "company_number_of_shares": 79418626,
        "price_change_sparkline": [
            [
                4.86,
                1706677200
            ],
            [
                5.25,
                1706763600
            ],
            [
                5.18,
                1706850000
            ],
            [
                4.95,
                1707109200
            ],
            [
                5.04,
                1707195600
            ],
            [
                5,
                1707282000
            ],
            [
                5.03,
                1707368400
            ],
            [
                5.68,
                1707454800
            ],
            [
                5.88,
                1707714000
            ],
            [
                5.62,
                1707800400
            ],
            [
                6.46,
                1707886800
            ],
            [
                6.86,
                1707973200
            ],
            [
                7.58,
                1708059600
            ],
            [
                7.52,
                1708405200
            ],
            [
                7.52,
                1708491600
            ],
            [
                9.7,
                1708578000
            ],
            [
                9.86,
                1708664400
            ],
            [
                9.9,
                1708923600
            ],
            [
                9.9,
                1709010000
            ],
            [
                9.95,
                1709096400
            ],
            [
                10.06,
                1709182800
            ],
            [
                10.75,
                1709269200
            ],
            [
                10.88,
                1709528400
            ],
            [
                10.93,
                1709614800
            ],
            [
                10.83,
                1709701200
            ],
            [
                10.37,
                1709787600
            ],
            [
                9.98,
                1709874000
            ],
            [
                9.73,
                1710129600
            ],
            [
                9.29,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4638,
        "drug_name": "TECENTRIQ (atezolizumab) + AVASTIN (bevacizumab) - IMpower150",
        "clinical_trial_id": "NCT02366143",
        "has_trial_insight_page": 0,
        "indication": "Non-squamous non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-06",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20181206005992\/en\/FDA-Approves-Genentech%E2%80%99s-Tecentriq-Combination-Avastin-Chemotherapy",
        "note": "FDA Approval announced December 6, 2018.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4796,
        "drug_name": "OXTELLAR XR (oxcarbazepine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Epilepsy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-14",
        "link": "http:\/\/ir.supernus.com\/news-releases\/news-release-details\/supernus-announces-fda-approval-snda-expand-oxtellar-xrr-label",
        "note": "FDA approval announced December 14, 2018 to expand label to include monotherapy treatment. ",
        "company_entity_id": 287,
        "company_ticker": "SUPN",
        "company_name": "Supernus Pharmaceuticals Inc.",
        "company_price": "32.9200",
        "company_change": 0.49,
        "company_percent_change": 1.51,
        "company_optionable": 1,
        "company_number_of_shares": 54734956,
        "price_change_sparkline": [
            [
                27.68,
                1706677200
            ],
            [
                27.86,
                1706763600
            ],
            [
                27.67,
                1706850000
            ],
            [
                27.31,
                1707109200
            ],
            [
                28.31,
                1707195600
            ],
            [
                27.24,
                1707282000
            ],
            [
                27.9,
                1707368400
            ],
            [
                27.91,
                1707454800
            ],
            [
                28.35,
                1707714000
            ],
            [
                27.11,
                1707800400
            ],
            [
                27.56,
                1707886800
            ],
            [
                28.66,
                1707973200
            ],
            [
                28.42,
                1708059600
            ],
            [
                28.05,
                1708405200
            ],
            [
                28.14,
                1708491600
            ],
            [
                27.935,
                1708578000
            ],
            [
                29.06,
                1708664400
            ],
            [
                29.5,
                1708923600
            ],
            [
                30.69,
                1709010000
            ],
            [
                31.08,
                1709096400
            ],
            [
                29.7,
                1709182800
            ],
            [
                31.01,
                1709269200
            ],
            [
                30.63,
                1709528400
            ],
            [
                30.35,
                1709614800
            ],
            [
                31.11,
                1709701200
            ],
            [
                30.81,
                1709787600
            ],
            [
                31.07,
                1709874000
            ],
            [
                32.43,
                1710129600
            ],
            [
                32.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4609,
        "drug_name": "HERZUMA (trastuzumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Herceptin biosimilar",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-14",
        "link": "https:\/\/bit.ly\/2PG30iW",
        "note": "FDA approval announced December 14, 2018.",
        "company_entity_id": 390,
        "company_ticker": "TEVA",
        "company_name": "Teva Pharmaceutical Industries Limited American Depositary Shares",
        "company_price": "13.4900",
        "company_change": 0.14,
        "company_percent_change": 1.05,
        "company_optionable": 1,
        "company_number_of_shares": 1121094011,
        "price_change_sparkline": [
            [
                12.1,
                1706677200
            ],
            [
                12.46,
                1706763600
            ],
            [
                12.28,
                1706850000
            ],
            [
                12.38,
                1707109200
            ],
            [
                12.25,
                1707195600
            ],
            [
                12.14,
                1707282000
            ],
            [
                12.09,
                1707368400
            ],
            [
                12.01,
                1707454800
            ],
            [
                12.91,
                1707714000
            ],
            [
                12.92,
                1707800400
            ],
            [
                13.17,
                1707886800
            ],
            [
                13.2,
                1707973200
            ],
            [
                13.02,
                1708059600
            ],
            [
                13.07,
                1708405200
            ],
            [
                13,
                1708491600
            ],
            [
                13.05,
                1708578000
            ],
            [
                12.89,
                1708664400
            ],
            [
                13.29,
                1708923600
            ],
            [
                13.3,
                1709010000
            ],
            [
                13.09,
                1709096400
            ],
            [
                13.15,
                1709182800
            ],
            [
                13.5,
                1709269200
            ],
            [
                13.44,
                1709528400
            ],
            [
                13.54,
                1709614800
            ],
            [
                13.53,
                1709701200
            ],
            [
                13.71,
                1709787600
            ],
            [
                13.62,
                1709874000
            ],
            [
                13.35,
                1710129600
            ],
            [
                13.49,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5336,
        "drug_name": "NPLATE (Romiplostim)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Immune Thrombocytopenia (Pediatric)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-14",
        "link": "http:\/\/investors.amgen.com\/phoenix.zhtml?c=61656&p=irol-newsArticle&ID=2380767",
        "note": "FDA approval announced December 14, 2018.",
        "company_entity_id": 372,
        "company_ticker": "AMGN",
        "company_name": "Amgen Inc.",
        "company_price": "276.5400",
        "company_change": 1.18,
        "company_percent_change": 0.43,
        "company_optionable": 1,
        "company_number_of_shares": 535918901,
        "price_change_sparkline": [
            [
                311.832823699025,
                1706677200
            ],
            [
                322.053272003295,
                1706763600
            ],
            [
                320.693853151174,
                1706850000
            ],
            [
                319.483275779212,
                1707109200
            ],
            [
                313.62884422628,
                1707195600
            ],
            [
                293.584858231498,
                1707282000
            ],
            [
                292.572736166415,
                1707368400
            ],
            [
                288.871544693121,
                1707454800
            ],
            [
                292.155980021969,
                1707714000
            ],
            [
                288.236487711108,
                1707800400
            ],
            [
                287.829654332006,
                1707886800
            ],
            [
                289.07,
                1707973200
            ],
            [
                283.7,
                1708059600
            ],
            [
                283.51,
                1708405200
            ],
            [
                283.46,
                1708491600
            ],
            [
                285.18,
                1708578000
            ],
            [
                289.18,
                1708664400
            ],
            [
                286.37,
                1708923600
            ],
            [
                278.49,
                1709010000
            ],
            [
                277.46,
                1709096400
            ],
            [
                273.83,
                1709182800
            ],
            [
                280.33,
                1709269200
            ],
            [
                279.39,
                1709528400
            ],
            [
                276.65,
                1709614800
            ],
            [
                276.59,
                1709701200
            ],
            [
                272.86,
                1709787600
            ],
            [
                273.75,
                1709874000
            ],
            [
                275.36,
                1710129600
            ],
            [
                276.54,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2971,
        "drug_name": "LYNPARZA (olaparib) - SOLO 1",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First-line ovarian cancer following platinum-based chemotherapy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-19",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2018\/lynparza-approved-by-us-fda-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer19122018.html",
        "note": "FDA Approval announced December 19, 2018.",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2971,
        "drug_name": "LYNPARZA (olaparib) - SOLO 1",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "First-line ovarian cancer following platinum-based chemotherapy",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-19",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2018\/lynparza-approved-by-us-fda-for-1st-line-maintenance-therapy-in-brca-mutated-advanced-ovarian-cancer19122018.html",
        "note": "FDA Approval announced December 19, 2018.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5104,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Merkel Cell Carcinoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2018-12-19",
        "link": "https:\/\/bit.ly\/2Exq5SW",
        "note": "FDA Approval announced December 19, 2018.",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    }
]